Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

By J. Lundgren, Jacqueline Neuhaus, Abdel Babiker, D. A. Cooper, D. Duprez, Wafaa Ei-Sadr, S. Emery, Fred M. Gordin, J. Kowalska, A. Phillips and 7 more. AIDS (London), 2008

921 citations recorded by the source corpus.

Subfields: Emergency Medicine, Epidemiology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/acd5c17f9dd9674c587492d313870ffc581f9857

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Emergency Medicine

1. Jason P. Fine
2. Peter C. Austin

In Infectious Diseases

1. Jason P. Fine
2. Peter C. Austin

Citations in the corpus

• Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. (2008, background): “A large, collaborative cohort study investigated the association of nRTI use with subsequent myocardial infarction.(74,75) After controlling for numerous factors, an increased risk of myocardial infarction associated with recent abacavir or didanosine use (relative rates, 1.”
• Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. (2010, background): “In contrast, no association was found between the risk of MI and exposure to nonnucleoside reversetranscriptase inhibitors (NNRTIs) [5] or any of the other NRTIs studied [6].”
• Competing risk regression models for epidemiologic data. (2009, background): “For example, the use of the antiretroviral drug abacavir has recently been associated with increased risk of myocardial infarction (45).”